Home  >  Products  >  CD22 (CD22 molecule) Blocking Peptide (the N terminal of CD22)(100ug)
CD22 (CD22 molecule) Blocking Peptide (the N terminal of CD22)(100ug)

CD22 (CD22 molecule) Blocking Peptide (the N terminal of CD22)(100ug)

Supplier: Aviva Systems Biology Incorporated
Star_fadedStar_fadedStar_fadedStar_fadedStar_faded
0 reviews | Write a Review Pencil
This is a synthetic peptide designed for use in combination with anti-CD22 Antibody (ARP59863_P050), made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
Reactivities: Human
Presku: AAP59863
Size: 100ug
Weight: 95kDa
Gene: 933
Format: Lyophilized powder
Target: CD22 mediates B-cell B-cell interactions. CD22 may be involved in the localization of B-cells in lymphoid tissues. CD22 binds sialylated glycoproteins; one of which is CD45. CD22 preferentially binds to alpha-2,6-linked sialic acid. The sialic acid recognition site can be masked by cis interactions with sialic acids on the same cell surface. Upon ligand induced tyrosine phosphorylation in the immune response CD22 seems to be involved in regulation of B-cell antigen receptor signaling. CD22 plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules.
Alternative names: FLJ22814; MGC130020; SIGLEC-2; SIGLEC2
See Full Product Listings >